Cargando…
Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada
OBJECTIVE: To assess outcomes over 24 months in Canadian patients with schizophrenia initiated on risperidone long-acting injection (RLAI) and participating in the electronic Schizophrenia Treatment Adherence Registry (e-STAR). MATERIALS AND METHODS: Patients with schizophrenia or schizoaffective di...
Autores principales: | Williams, Richard, Chandrasena, Ranjith, Beauclair, Linda, Luong, Doanh, Lam, Annette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942298/ https://www.ncbi.nlm.nih.gov/pubmed/24600227 http://dx.doi.org/10.2147/NDT.S54740 |
Ejemplares similares
-
Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
por: Apiquian, Rogelio, et al.
Publicado: (2011) -
Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007) -
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louzã, Mário Rodrigues, et al.
Publicado: (2011) -
Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database
por: Lambert, Tim, et al.
Publicado: (2012) -
Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
por: Tchobaniouk, Lesia V, et al.
Publicado: (2019)